How case based education elevated clinical performance in metastatic breast cancer management: A study for TROP2 directed antibody drug conjugates

Background: The treatment landscape of metastatic breast cancer (mBC) has advanced with antibody-drug conjugates (ADCs), notably the TROP2-directed agents sacituzumab govitecan and datopotamab deruxtecan. These options have extended treatment potential for patients with HER2- mBC. However, rapid updates pose challenges for clinicians in adopting evidence-based, personalized strategies. Objective: To assess whether a digital, case-based, short-format CME activity could address knowledge and competence (K/C) gaps regarding the evidence-based use of TROP2-directed ADCs in HER2- mBC. Methods: A 15-minute, case-based, accredited online activity (“Opportunities to Personalize Care: Making the Case for TROP2-Directed ADCs in HR+, HER2- mBC”) launched March 28, 2025. Global academic and community oncologists completed pre-/post-assessments measuring K/C outcomes. A qualitative follow-up questionnaire, 4 weeks post-launch, evaluated practice changes and implementation behaviors. Results: As of June 3, 2025, 4,073 learners participated. Post-activity data showed a 20% mean improvement in K/C scores. Participants improved notably in identifying appropriate patients and applying ADCs in alignment with clinical evidence. The lowest baseline knowledge area-patient identification-showed marked gains, though further reinforcement may optimize impact in practice. Notably, 73% reported practice changes attributable to the activity. Post-education assessment revealed increased implementation of personalized and evidence-based treatment decision-making and adverse event management (Table 1). Conclusion: This case-based CME activity effectively improved clinician K/C regarding TROP2-directed ADCs for HER2- mBC and supported sustained practice change. Personalized, digital education formats may accelerate integration of newly available and emerging therapies into oncology care. Table 1: Impact of Education on Practice Change Change in practice Initial analysis, %; n=33 4 week F/U after participation, %; N=55 Identify appropriate patients with HR+, HER2-negative mBC who are candidates for TROP2-directed ADCs 58 71 Recognize appropriate characteristics to select between ADCs for patients with HR+, HER2-negative mBC 64 85 Proactively implement best practices to manage AEs for patients with mBC on TROP2-directed ADCs 39 69 Apply guideline recommendations to select TROP2 directed ADCs for patients with HR+, HER2-negative metastatic breast cancer 48 56